845885-80-5 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
5-(4-Cyanophenyl)nicotinic acid is used as a research compound for studying nicotinic acid receptors, which are potential drug targets for various therapeutic applications.
Used in Anti-Inflammatory Applications:
5-(4-Cyanophenyl)nicotinic acid is being investigated for its potential as an anti-inflammatory agent, which could be useful in the treatment of various inflammatory conditions.
Used in Metabolic and Cardiovascular Disease Treatment:
5-(4-Cyanophenyl)nicotinic acid is also being studied for its role in the treatment of metabolic and cardiovascular diseases, given its potential therapeutic effects in these areas.
Used in Preclinical Studies:
5-(4-Cyanophenyl)nicotinic acid has shown promise in preclinical studies, indicating its potential for future therapeutic applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 845885-80-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,8,8 and 5 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 845885-80:
(8*8)+(7*4)+(6*5)+(5*8)+(4*8)+(3*5)+(2*8)+(1*0)=225
225 % 10 = 5
So 845885-80-5 is a valid CAS Registry Number.
845885-80-5Relevant articles and documents
Subtype-selective Nav1.8 sodium channel blockers: Identification of potent, orally active nicotinamide derivatives
Kort, Michael E.,Atkinson, Robert N.,Thomas, James B.,Drizin, Irene,Johnson, Matthew S.,Secrest, Matthew A.,Gregg, Robert J.,Scanio, Marc J.C.,Shi, Lei,Hakeem, Ahmed H.,Matulenko, Mark A.,Chapman, Mark L.,Krambis, Michael J.,Liu, Dong,Shieh, Char-Chang,Zhang, Xufeng,Simler, Gricelda,Mikusa, Joseph P.,Zhong, Chengmin,Joshi, Shailen,Honore, Prisca,Roeloffs, Rosemarie,Werness, Stephen,Antonio, Brett,Marsh, Kennan C.,Faltynek, Connie R.,Krafte, Douglas S.,Jarvis, Michael F.,Marron, Brian E.
scheme or table, p. 6812 - 6815 (2011/01/04)
A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Nav1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain.